Recombinant Human IL-13 Protein, Active, Low Endotoxin

Product Overview Product Name Recombinant Human IL-13 Protein Target Symbol IL13 Alternative Names Interleukin 13, IL13, P600, NC30, MGC116786, MGC116788, MGC116789 Accession Number AAK53823 Expression System E. coli. Molecular Weight 12.7 kDa (predicted) Sequence Ser19-Asn132, with an N-terminal Met Purity >98% by SDS-PAGE and quantitative densitometry by CoomassiePurity ® Blue staining Activity Determined by a cell proliferation assay using human TF-1 cells. The ED50 for this effect is typically <2 ng/mL Formulation Lyophilized from sterile PBS with Trehalose, pH 7.4 Endotoxin Level <0.005 EU per 1 μg of the protein as determined by the LAL method Shipping Shipped at ambient temperature. Stability & Storage 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. Reconstitution Reconstitute at 100 ug/mL in sterile PBS. Target Function Interleukin-13 (IL-13) is a cytokine primarily produced by T helper type 2 (Th2) cells, as well as other immune cells like mast cells, basophils, and eosinophils. It promotes the activation, differentiation, and survival of B cells, including Ig class switching. IL-13 enhances the survival and migration of epithelial cells in various organs, coupling this with its anti-parasitic Th2-mediated response in these organs. IL-13 signaling occurs when it binds IL13RA1 (CD213A1) which heterodimerizes with IL-4R alpha (CD124) to activate the JAK/STAT signal pathway. Tissue Specificity IL-13 expression has been identified in gastrointestinal and lung epithelial tissue. Cellular Localization Secreted protein Involvement In Disease Dysregulation of IL-13 is associated with asthma, allergic rhinitis, atopic dermatitis, scleroderma, inflammatory bowel disease (IBD), and allergic conjunctivitis.